NasdaqGS:RVMDBiotechs
Revolution Medicines (RVMD): Evaluating Valuation After First Patient Randomized in Pivotal RASolute 304 Trial
Revolution Medicines (RVMD) just hit an important clinical milestone, randomizing the first patient in its RASolute 304 Phase 3 trial of daraxonrasib for post-surgery pancreatic cancer patients after chemotherapy.
See our latest analysis for Revolution Medicines.
The news lands as the stock trades around $78.78, with a powerful 90 day share price return of 80.94 percent and a three year total shareholder return of 257.44 percent, signaling strong, building momentum around Revolution Medicines...